The legal action centers on claims that Zoetis violated federal securities laws by issuing false and misleading statements. According to the complaint, the company obscured declining prescription growth for its Librela medication, which faced headwinds following FDA warnings regarding neurological complications in dogs. Beyond the safety concerns, the filing alleges that the company’s flagship dermatology treatments, Apoquel and Cytopoint, and its Trio product, lost significant market share to emerging competitors.

Investors seeking to participate in the litigation must act before the July 27, 2026, deadline. Brian Schall of the Los Angeles-based firm is leading the outreach, inviting affected parties to discuss their rights and potential recovery options. While the class has yet to be certified by the court, those who held shares during the specified window remain eligible to join the action as the case proceeds.